Superior Overall Survival in Patients with Colorectal Cancer, Regular Aspirin Use, and Combined Wild-Type PIK3CA and KRAS-Mutated Tumors

The impact of aspirin use after the diagnosis of colorectal cancer is unknown. Among others, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) mutational status was proposed as a molecular biomarker for the response to adjuvant aspirin therapy. However, prognostic data...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2021-10, Vol.13 (19), p.4959
Main Authors: Gebauer, Leonie, Nist, Andrea, Mernberger, Marco, Stiewe, Thorsten, Moll, Roland, Stabla, Kathleen, Klinge, Uwe, Mack, Elisabeth, Brendel, Cornelia, Neubauer, Andreas
Format: Article
Language:English
Subjects:
Aspirin
Biomarkers
Cancer
Cardiovascular disease
Colorectal cancer
Colorectal carcinoma
Diagnosis
K-Ras protein
Kinases
Medical prognosis
Metastasis
Mutation
Next-generation sequencing
Patients
Phosphatidylinositol 4,5-diphosphate
Primary care
Software
Statistical analysis
Surgery
Survival
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The impact of aspirin use after the diagnosis of colorectal cancer is unknown. Among others, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) mutational status was proposed as a molecular biomarker for the response to adjuvant aspirin therapy. However, prognostic data on aspirin use after a colorectal cancer diagnosis in relation to KRAS mutational status is limited. In a single-center retrospective study, we obtained KRAS and PIK3CA mutational status in a cohort of 153 patients with a first diagnosis of colorectal cancer receiving tumor surgery with curative intent. PIK3CA mutational status was determined by pyrosequencing, and KRAS mutational status was determined by next-generation sequencing. Clinicopathological data and survival data were assessed using patient records and reporting registers. We observed a significant 10-year overall survival benefit in patients with aspirin use and combined wild-type PIK3CA and mutated-KRAS tumors (HR = 0.38; 95% CI = 0.17–0.87; p = 0.02), but not in patients without aspirin use. Our data indicate a benefit of aspirin usage particularly for patients with combined wild-type PIK3CA and mutated-KRAS tumor characteristics.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13194959